{"id":"cefotaxime","rwe":[{"pmid":"41901706","year":"2026","title":"Fluoroquinolone-Resistant Avian Pathogenic Escherichia coli Isolated from Asymptomatic Broiler Chickens in a Slaughterhouse in Northern Thailand.","finding":"","journal":"Pathogens (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41893986","year":"2026","title":"Evaluation of the B-lactam antibiotic concentration in the early phase of treatment of patients with suspected sepsis at the emergency department.","finding":"","journal":"Infection","studyType":"Clinical Study"},{"pmid":"41892484","year":"2026","title":"Antimicrobial Resistance and ESBL-Associated Predictors Among Uropathogens: A 2019-2024 Isolate-Level Study.","finding":"","journal":"Antibiotics (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41890979","year":"2026","title":"Phenotypic and genotypic characterization of Acinetobacter junii and Acinetobacter nosocomialis isolated from humans, animals, and the environment in Lagos, Nigeria.","finding":"","journal":"One health (Amsterdam, Netherlands)","studyType":"Clinical Study"},{"pmid":"41890384","year":"2026","title":"Analysis of Antimicrobial Utilization Pattern in Neonatal Intensive Care Unit: A Prospective Observational Study.","finding":"","journal":"Journal of pharmacy & bioallied sciences","studyType":"Clinical Study"}],"_fda":{"id":"425c90b3-5006-427e-95f6-93ee7918fb8b","set_id":"8efe3bd0-c43a-2bd6-e053-2a95a90a92fa","openfda":{"unii":["258J72S7TZ"],"route":["INTRAMUSCULAR","INTRAVENOUS"],"rxcui":["1656313","1656318"],"spl_id":["425c90b3-5006-427e-95f6-93ee7918fb8b"],"brand_name":["Cefotaxime"],"spl_set_id":["8efe3bd0-c43a-2bd6-e053-2a95a90a92fa"],"package_ndc":["21586-011-01","21586-011-02","21586-012-01","21586-012-02"],"product_ndc":["21586-011","21586-012"],"generic_name":["CEFOTAXIME INJECTION"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["CEFOTAXIME SODIUM"],"manufacturer_name":["SteriMax Inc."],"is_original_packager":[true]},"version":"6","effective_time":"20241212","spl_product_data_elements":["Cefotaxime cefotaxime injection CEFOTAXIME SODIUM CEFOTAXIME Cefotaxime cefotaxime injection CEFOTAXIME SODIUM CEFOTAXIME"],"health_care_provider_letter":["IMPORTANT PRESCRIBING INFORMATION December 11, 2024 Temporary Importation of Cefotaxime for Injection to Address Drug Shortage Dear Healthcare Professional: Due to the current critical shortage of Cefotaxime for Injection products in the United States (U.S.) market, SteriMax Inc. (SteriMax), in conjunction with Provepharm, Inc. (Provepharm) and Direct Success, Inc. (Direct Success) is coordinating with the U.S. Food and Drug Administration (FDA) to increase the availability of the drug. SteriMax has initiated temporary importation of non-FDA approved Cefotaxime for Injection (1 g/vial, and 2 g/vial) into the U.S. market. The Cefotaxime for Injection from SteriMax is marketed in Canada and is manufactured at an FDA-inspected facility that complies with current Good Manufacturing Practice requirements. At this time, no other entity except Provepharm or its distributor Direct Success is authorized by the FDA to import or distribute SteriMax’s Cefotaxime for Injection in the United States. FDA has not approved SteriMax’s Cefotaxime for Injection in the United States. Effective immediately, Provepharm will distribute the following presentations of SteriMax’s Cefotaxime for Injection to address the critical shortage: Note: DIN refers to Drug Identification Number for products approved by Health Canada SteriMax Cefotaxime for Injection 1 g/vial (as cefotaxime sodium) DIN: 02434091 (Canada) NDC 21586-011-2 2 g/vial (as cefotaxime sodium) DIN: 02434105 (Canada) NDC 21586-012-2 The barcode on the imported product label may not register accurately on the U.S. scanning systems. Institutions should manually input the imported product information into their systems and confirm that the barcode, if scanned, provides correct information. Alternative procedures should be followed to assure that the correct drug product is being used and administered to individual patients. In addition, the packaging of the imported product does not include serialization information. SteriMax’s Cefotaxime for Injection does not meet the Drug Supply Chain Security Act (DSCSA) requirements for the Interoperable Exchange of Information for Tracing of Human, Finished Prescription Drugs. The vial and carton labels will display the text used and approved for marketing the products in Canada with both English and French translations. It is important to note that there are differences in the format and content of the labeling between the US approved product and SteriMax’s Cefotaxime for Injection. Please see the product comparison tables at the end of this letter. Cefotaxime for Injection is available only by prescription in the U.S. Please refer to the package insert for the FDA-approved Cefotaxime for Injection drug product for full prescribing information. Finally, please ensure that your staff and others in your institution who may be involved in the administration of Cefotaxime for Injection receive a copy of this letter and review the information. If you have any questions about the information contained in this letter, any quality related problems, or questions on the use of SteriMax’s Cefotaxime for Injection, please contact SteriMax Inc. Customer Service at 1-800-881-3550. To place an order, please contact Direct Success at Distribution@DSuccess.com or 1-877-404-3338. Healthcare providers should report adverse events associated with the use of SteriMax’s Cefotaxime for Injection to Provepharm at 1-833-684-3234. Adverse events or quality problems experienced with the use of this product may also be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail, or by fax: Complete and submit the report Online: www.fda.gov/medwatch/report.htm Regular mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form or submit by fax to 1-800-FDA-0178. We remain at your disposal to answer any questions you may have about our product; and provide more information if needed. Sincerely, Ritesh Acharya Chief Scientific Officer SteriMax Inc. sign1 prodcompare1 prodcompare2 prodcompare3"],"health_care_provider_letter_table":["<table><caption/><tfoot><tr styleCode=\"First Last\"><td styleCode=\"Toprule\" colspan=\"3\">Note: DIN refers to Drug Identification Number for products approved by Health Canada</td></tr></tfoot><tbody><tr><td styleCode=\"Lrule Rrule\" colspan=\"3\" align=\"center\"><content styleCode=\"bold\">SteriMax Cefotaxime for Injection</content></td></tr><tr><td styleCode=\"Botrule Lrule Rrule Toprule\"> 1 g/vial (as cefotaxime sodium)</td><td styleCode=\"Botrule Rrule Toprule\"> DIN: 02434091  (Canada)</td><td styleCode=\"Botrule Rrule Toprule\" align=\"center\">NDC 21586-011-2</td></tr><tr><td styleCode=\"Lrule Rrule\"> 2 g/vial (as cefotaxime sodium)</td><td styleCode=\"Botrule Rrule\"> DIN: 02434105  (Canada)</td><td styleCode=\"Botrule Rrule\" align=\"center\">NDC 21586-012-2</td></tr></tbody></table>"],"package_label_principal_display_panel":["Cefotaxime for Injection - 1 g per vial Sterile/Stérile DIN 02434091 cefoTAXime Sodium for Injection, BP 1 g per vial Powder for solution Antibiotic For IM or IV Use Only Preservative Free Single use vial. Discard unused portion. The stopper is not made with natural rubber latex. Steri ​Max Inc. 1gvial","Cefotaxime for Injection - 2 g per vial Sterile/Stérile DIN 02434105 cefoTAXime Sodium for Injection, BP 2 g per vial Powder for solution Antibiotic For Intramuscular or Intravenous Use Only Reconstitute before use Preservative Free Single use vial. Discard unused portion. The stopper is not made with natural rubber latex. Steri Max Inc. 2gvial"]},"tags":[{"label":"Cephalosporin Antibacterial","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"J01DD01","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Intramuscular","category":"route"},{"label":"Injection","category":"form"},{"label":"Powder","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Bacterial arthritis","category":"indication"},{"label":"Bacterial infection due to Klebsiella pneumoniae","category":"indication"},{"label":"Bacterial infection due to Serratia","category":"indication"},{"label":"Bacterial meningitis","category":"indication"},{"label":"Bacterial pneumonia","category":"indication"},{"label":"Bacterial septicemia","category":"indication"},{"label":"Sterimax","category":"company"},{"label":"Approved 1980s","category":"decade"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"360 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"323 reports"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"278 reports"},{"date":"","signal":"DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS","source":"FDA FAERS","actionTaken":"239 reports"},{"date":"","signal":"ACUTE KIDNEY INJURY","source":"FDA FAERS","actionTaken":"192 reports"},{"date":"","signal":"THROMBOCYTOPENIA","source":"FDA FAERS","actionTaken":"148 reports"},{"date":"","signal":"NEUTROPENIA","source":"FDA FAERS","actionTaken":"145 reports"},{"date":"","signal":"CONDITION AGGRAVATED","source":"FDA FAERS","actionTaken":"133 reports"},{"date":"","signal":"SEPSIS","source":"FDA FAERS","actionTaken":"127 reports"},{"date":"","signal":"TOXIC EPIDERMAL NECROLYSIS","source":"FDA FAERS","actionTaken":"125 reports"}],"commonSideEffects":[],"contraindications":["Acute nephropathy","Pseudomembranous enterocolitis"],"specialPopulations":{"Pregnancy":"No evidence of embryotoxicity or teratogenicity was seen in these studies.","Geriatric use":"No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.","Paediatric use":"See Precautions above regarding perivascular extravasation.","Renal impairment":"This drug is known to be substantially excreted by the kidney, "}},"trials":[],"aliases":[],"company":"Sterimax","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CEFOTAXIME","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:35:38.638459+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:35:44.755131+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:35:37.267671+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CEFOTAXIME","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:35:45.485162+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:35:36.240952+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:35:36.241005+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:35:46.974530+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Bacterial penicillin-binding protein inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:35:46.059536+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1010/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:35:45.952052+00:00"}},"allNames":"claforan","offLabel":[],"synonyms":["cefotaxime","cefotaxime sodium","cephotaxime","cefotaxime sodium salt"],"timeline":[{"date":"1981-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from SANOFI AVENTIS US to Sterimax"},{"date":"1981-03-11","type":"positive","source":"DrugCentral","milestone":"FDA approval (Sanofi Aventis Us)"},{"date":"1985-05-20","type":"positive","source":"FDA Orange Book","milestone":"Claforan In Dextrose 5% In Plastic Container approved — EQ 20MG BASE/ML"},{"date":"2004-07-29","type":"positive","source":"FDA Orange Book","milestone":"Cefotaxime And Dextrose 2.4% In Plastic Container approved — EQ 2GM BASE"},{"date":"2006-08-10","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 6 manufacturers approved"}],"aiSummary":"Claforan (Cefotaxime) is a cephalosporin antibacterial drug developed by Sanofi Aventis US and currently owned by Sterimax. It is a small molecule that has been FDA-approved since 1981 for various bacterial infections, including bacterial arthritis, meningitis, and septicemia. Claforan is off-patent and has multiple generic manufacturers. Key safety considerations include its short half-life of 1.2 hours. Claforan is a broad-spectrum antibiotic that treats a range of bacterial infections.","brandName":"Claforan","ecosystem":[{"indication":"Bacterial arthritis","otherDrugs":[{"name":"ceftriaxone","slug":"ceftriaxone","company":""}],"globalPrevalence":null},{"indication":"Bacterial infection due to Klebsiella pneumoniae","otherDrugs":[{"name":"alatrofloxacin","slug":"alatrofloxacin","company":"Pfizer"},{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"azlocillin","slug":"azlocillin","company":"Bayer Pharmaceuticals Corp"},{"name":"aztreonam","slug":"aztreonam","company":"Bristol Myers Squibb"}],"globalPrevalence":null},{"indication":"Bacterial infection due to Serratia","otherDrugs":[{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"azlocillin","slug":"azlocillin","company":"Bayer Pharmaceuticals Corp"},{"name":"aztreonam","slug":"aztreonam","company":"Bristol Myers Squibb"},{"name":"ceftizoxime","slug":"ceftizoxime","company":""}],"globalPrevalence":null},{"indication":"Bacterial meningitis","otherDrugs":[{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"ceftazidime","slug":"ceftazidime","company":"Covis Injectables"},{"name":"ceftriaxone","slug":"ceftriaxone","company":""}],"globalPrevalence":null},{"indication":"Bacterial pneumonia","otherDrugs":[{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"azithromycin","slug":"azithromycin","company":""}],"globalPrevalence":null},{"indication":"Bacterial septicemia","otherDrugs":[{"name":"Polymyxin B","slug":"polymyxin-b","company":"Monarch Pharms"},{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"azlocillin","slug":"azlocillin","company":"Bayer Pharmaceuticals Corp"}],"globalPrevalence":null},{"indication":"Bacterial urinary infection","otherDrugs":[{"name":"amikacin","slug":"amikacin","company":"Apothecon"},{"name":"amoxicillin","slug":"amoxicillin","company":"Apothecon"},{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"avibactam","slug":"avibactam","company":"Cerexa Inc"}],"globalPrevalence":null},{"indication":"Bacteroides Endometritis","otherDrugs":[{"name":"cefotetan","slug":"cefotetan","company":""},{"name":"cefoxitin","slug":"cefoxitin","company":""},{"name":"clavulanic acid","slug":"clavulanic-acid","company":"Dr Reddys Labs Inc"},{"name":"metronidazole","slug":"metronidazole","company":"Gd Searle Llc"}],"globalPrevalence":null}],"mechanism":{"novelty":"First-in-class","modality":"Small Molecule","drugClass":"Cephalosporin Antibacterial","explanation":"","oneSentence":"","technicalDetail":"Cefotaxime exerts its antibacterial effect by binding to penicillin-binding proteins (PBPs) located inside the bacterial cell wall, thereby inhibiting the cross-linking of peptidoglycan chains and ultimately leading to cell lysis and death."},"commercial":{"launchDate":"1981","_launchSource":"DrugCentral (FDA 1981-03-11, SANOFI AVENTIS US)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/546","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CEFOTAXIME","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CEFOTAXIME","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T09:20:26.777365","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:35:47.901823+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"ceftazidime","drugSlug":"ceftazidime","fdaApproval":"1985-07-19","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ceftriaxone","drugSlug":"ceftriaxone","fdaApproval":"1984-12-21","genericCount":26,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cefmenoxime","drugSlug":"cefmenoxime","fdaApproval":"1987-12-30","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"latamoxef","drugSlug":"latamoxef","fdaApproval":"","relationship":"same-class"},{"drugName":"ceftizoxime","drugSlug":"ceftizoxime","fdaApproval":"1983-09-15","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cefixime","drugSlug":"cefixime","fdaApproval":"1989-04-28","patentExpiry":"Dec 14, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"cefpiramide","drugSlug":"cefpiramide","fdaApproval":"1989-01-31","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"cefoperazone","drugSlug":"cefoperazone","fdaApproval":"1982-11-18","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cefpodoxime proxetil","drugSlug":"cefpodoxime-proxetil","fdaApproval":"1992-08-07","genericCount":7,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ceftibuten","drugSlug":"ceftibuten","fdaApproval":"1995-12-20","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"cefdinir","drugSlug":"cefdinir","fdaApproval":"1997-12-04","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"cefditoren pivoxil","drugSlug":"cefditoren-pivoxil","fdaApproval":"2001-08-29","patentStatus":"Unknown","relationship":"same-class"}],"genericName":"cefotaxime","indications":{"approved":[{"name":"Bacterial arthritis","source":"DrugCentral","snomedId":48245008,"regulator":"FDA","eligibility":"Not specified"},{"name":"Bacterial infection due to Klebsiella pneumoniae","source":"DrugCentral","snomedId":186435004,"regulator":"FDA","eligibility":"Not specified"},{"name":"Bacterial infection due to Serratia","source":"DrugCentral","snomedId":71120004,"regulator":"FDA","eligibility":"Not specified"},{"name":"Bacterial meningitis","source":"DrugCentral","snomedId":95883001,"regulator":"FDA","eligibility":"Not specified"},{"name":"Bacterial pneumonia","source":"DrugCentral","snomedId":53084003,"regulator":"FDA","eligibility":"Not specified"},{"name":"Bacterial septicemia","source":"DrugCentral","snomedId":10001005,"regulator":"FDA","eligibility":"Not specified"},{"name":"Bacterial urinary infection","source":"DrugCentral","snomedId":312124009,"regulator":"FDA","eligibility":"Not specified"},{"name":"Bacteroides Endometritis","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Not specified"},{"name":"Bacteroides Pelvic Cellulitis","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Not specified"},{"name":"Bacteroides Pelvic Inflammatory Disease","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Not specified"},{"name":"Cesarean Section Infection Prevention","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Citrobacter Urinary Tract Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Clostridium Endometritis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Clostridium Pelvic Cellulitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Clostridium Pelvic Inflammatory Disease","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Clostridium Peritonitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"E. Coli Endometritis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"E. Coli Pelvic Cellulitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"E. Coli Pelvic Inflammatory Disease","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"E. Coli Peritonitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Enterobacter Endometritis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Enterobacter Pelvic Inflammatory Disease","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Enterobacter Pneumonia","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Enterococcus Endometritis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Enterococcus Pelvic Cellulitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Enterococcus Pelvic Inflammatory Disease","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Enterococcus Urinary Tract Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Escherichia coli meningitis","source":"DrugCentral","snomedId":192655005,"regulator":"FDA"},{"name":"Escherichia coli urinary tract infection","source":"DrugCentral","snomedId":301011002,"regulator":"FDA"},{"name":"Female genital tract infection","source":"DrugCentral","snomedId":125585007,"regulator":"FDA"},{"name":"Fusobacterium Endometritis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Fusobacterium Pelvic Inflammatory Disease","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"H. Influenzae Meningitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Haemophilus Influenzae Type B Infections","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Haemophilus Parainfluenzae Pneumonia","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Haemophilus influenzae pneumonia","source":"DrugCentral","snomedId":70036007,"regulator":"FDA"},{"name":"Infection of bone","source":"DrugCentral","snomedId":111253001,"regulator":"FDA"},{"name":"Infection of skin AND/OR subcutaneous tissue","source":"DrugCentral","snomedId":19824006,"regulator":"FDA"},{"name":"Infectious disease of abdomen","source":"DrugCentral","snomedId":128070006,"regulator":"FDA"},{"name":"Klebsiella Endometritis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Klebsiella Pelvic Inflammatory Disease","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Klebsiella Pneumoniae Peritonitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Klebsiella cystitis","source":"DrugCentral","snomedId":60867007,"regulator":"FDA"},{"name":"Lower respiratory tract infection","source":"DrugCentral","snomedId":50417007,"regulator":"FDA"},{"name":"Meningitis due to Klebsiella mobilis","source":"DrugCentral","snomedId":420585007,"regulator":"FDA"},{"name":"Meningococcal meningitis","source":"DrugCentral","snomedId":192644005,"regulator":"FDA"},{"name":"Morganella Morganii Urinary Tract Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Neonatal Group B Streptococcal Septicemia","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Neonatal conjunctivitis","source":"DrugCentral","snomedId":34298002,"regulator":"FDA"},{"name":"Neonatal meningitis","source":"DrugCentral","snomedId":276674008,"regulator":"FDA"},{"name":"Neonatal pneumonia","source":"DrugCentral","snomedId":233619008,"regulator":"FDA"},{"name":"Peritonitis","source":"DrugCentral","snomedId":48661000,"regulator":"FDA"},{"name":"Pneumonia due to Escherichia coli","source":"DrugCentral","snomedId":51530003,"regulator":"FDA"},{"name":"Pneumonia due to Pseudomonas","source":"DrugCentral","snomedId":41381004,"regulator":"FDA"},{"name":"Pneumonia due to Streptococcus","source":"DrugCentral","snomedId":34020007,"regulator":"FDA"},{"name":"Prevention of Perioperative Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Proteus Endometritis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Proteus Mirabilis Osteomyelitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Proteus Pelvic Inflammatory Disease","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Proteus Peritonitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Proteus pneumonia","source":"DrugCentral","snomedId":195888009,"regulator":"FDA"},{"name":"Proteus urinary tract infection","source":"DrugCentral","snomedId":301012009,"regulator":"FDA"},{"name":"Providencia Urinary Tract Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Pseudomonas Aeruginosa Urinary Tract Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Sepsis due to Staphylococcus aureus","source":"DrugCentral","snomedId":448417001,"regulator":"FDA"},{"name":"Sepsis of the newborn","source":"DrugCentral","snomedId":206376005,"regulator":"FDA"},{"name":"Septicemia due to Escherichia coli","source":"DrugCentral","snomedId":9323009,"regulator":"FDA"},{"name":"Septicemia due to Serratia","source":"DrugCentral","snomedId":82091000,"regulator":"FDA"},{"name":"Serratia Urinary Tract Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Staphylococcal pneumonia","source":"DrugCentral","snomedId":22754005,"regulator":"FDA"},{"name":"Staphylococcus Aureus Urinary Tract Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Staphylococcus Endometritis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Staphylococcus Epidermidis Urinary Tract Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Staphylococcus Pelvic Inflammatory Disease","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Streptococcal Peritonitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Streptococcal meningitis","source":"DrugCentral","snomedId":4510004,"regulator":"FDA"},{"name":"Streptococcal septicemia","source":"DrugCentral","snomedId":29577008,"regulator":"FDA"},{"name":"Streptococcus Osteomyelitis","source":"DrugCentral","snomedId":"","regulator":"FDA"}],"offLabel":[{"name":"Acute gonococcal cervicitis","source":"DrugCentral","drugName":"CEFOTAXIME","evidenceCount":2,"evidenceLevel":"emerging"},{"name":"Acute gonococcal urethritis","source":"DrugCentral","drugName":"CEFOTAXIME","evidenceCount":17,"evidenceLevel":"moderate"},{"name":"Disseminated Gonococcal Infection","source":"DrugCentral","drugName":"CEFOTAXIME","evidenceCount":71,"evidenceLevel":"strong"},{"name":"Gonorrhea of rectum","source":"DrugCentral","drugName":"CEFOTAXIME","evidenceCount":21,"evidenceLevel":"moderate"},{"name":"Infection by Yersinia enterocolitica","source":"DrugCentral","drugName":"CEFOTAXIME","evidenceCount":86,"evidenceLevel":"strong"},{"name":"Lyme Disease of the Central Nervous System","source":"DrugCentral","drugName":"CEFOTAXIME","evidenceCount":51,"evidenceLevel":"strong"},{"name":"Lyme arthritis","source":"DrugCentral","drugName":"CEFOTAXIME","evidenceCount":494,"evidenceLevel":"strong"},{"name":"Lyme carditis","source":"DrugCentral","drugName":"CEFOTAXIME","evidenceCount":45,"evidenceLevel":"moderate"},{"name":"Lyme disease","source":"DrugCentral","drugName":"CEFOTAXIME","evidenceCount":494,"evidenceLevel":"strong"},{"name":"Pseudotuberculosis","source":"DrugCentral","drugName":"CEFOTAXIME","evidenceCount":19,"evidenceLevel":"moderate"},{"name":"Pyrexia of unknown origin","source":"DrugCentral","drugName":"CEFOTAXIME"},{"name":"Ventilator-acquired pneumonia","source":"DrugCentral","drugName":"CEFOTAXIME"}],"pipeline":[]},"currentOwner":"Sterimax","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"ceftazidime","brandName":"ceftazidime","genericName":"ceftazidime","approvalYear":"1985","relationship":"same-class"},{"drugId":"ceftriaxone","brandName":"ceftriaxone","genericName":"ceftriaxone","approvalYear":"1984","relationship":"same-class"},{"drugId":"cefmenoxime","brandName":"cefmenoxime","genericName":"cefmenoxime","approvalYear":"1987","relationship":"same-class"},{"drugId":"latamoxef","brandName":"latamoxef","genericName":"latamoxef","approvalYear":"","relationship":"same-class"},{"drugId":"ceftizoxime","brandName":"ceftizoxime","genericName":"ceftizoxime","approvalYear":"1983","relationship":"same-class"},{"drugId":"cefixime","brandName":"cefixime","genericName":"cefixime","approvalYear":"1989","relationship":"same-class"},{"drugId":"cefpiramide","brandName":"cefpiramide","genericName":"cefpiramide","approvalYear":"1989","relationship":"same-class"},{"drugId":"cefoperazone","brandName":"cefoperazone","genericName":"cefoperazone","approvalYear":"1982","relationship":"same-class"},{"drugId":"cefpodoxime-proxetil","brandName":"cefpodoxime proxetil","genericName":"cefpodoxime proxetil","approvalYear":"1992","relationship":"same-class"},{"drugId":"ceftibuten","brandName":"ceftibuten","genericName":"ceftibuten","approvalYear":"1995","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07207876","phase":"","title":"Study of Ceftriaxone and Benzathine Penicillin G During Pregnancy","status":"RECRUITING","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2026-02-16","conditions":["Pregnancy"],"enrollment":110,"completionDate":"2027-05-17"},{"nctId":"NCT07484633","phase":"PHASE4","title":"A Randomised Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients.","status":"NOT_YET_RECRUITING","sponsor":"Semmelweis University","startDate":"2026-04","conditions":["Infection","Sepsis","NICU","PICU","Beta Lactams"],"enrollment":110,"completionDate":"2028-04"},{"nctId":"NCT07485010","phase":"PHASE2","title":"Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial","status":"NOT_YET_RECRUITING","sponsor":"The University of Queensland","startDate":"2027-04","conditions":["Mycobacterium Abscessus Pulmonary Disease","Mycobacterium Abscessus Infection","Non-Tuberculous Mycobacterial (NTM) Infections","Non-Tuberculous Mycobacteria Pulmonary Disease"],"enrollment":300,"completionDate":"2031-07"},{"nctId":"NCT06406114","phase":"PHASE2","title":"Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2025-05-05","conditions":["Drug Allergy","Cephalosporin Allergy","Drug Hypersensitivity","Antibiotic Allergy","Beta Lactam Adverse Reaction","Drug-Induced Anaphylaxis","Cephalosporin Reaction"],"enrollment":300,"completionDate":"2028-12-31"},{"nctId":"NCT06611111","phase":"EARLY_PHASE1","title":"Ceftriaxone Pulse Dose for Post-Treatment Lyme Disease","status":"RECRUITING","sponsor":"State University of New York - Upstate Medical University","startDate":"2025-02-03","conditions":["Post-Treatment Lyme Disease"],"enrollment":44,"completionDate":"2026-12"},{"nctId":"NCT06712641","phase":"PHASE4","title":"Aminoglycosides in Early Sepsis","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Akershus","startDate":"2026-04","conditions":["Sepsis"],"enrollment":1900,"completionDate":"2033-05"},{"nctId":"NCT06860802","phase":"PHASE1","title":"Precision Antibiotic Dosing for Appendectomy","status":"RECRUITING","sponsor":"University of Michigan","startDate":"2025-02-28","conditions":["Appendicitis (Diagnosis)"],"enrollment":46,"completionDate":"2026-09-30"},{"nctId":"NCT06494072","phase":"PHASE4","title":"Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2024-08-22","conditions":["Community Acquired Pneumonia in Children"],"enrollment":236,"completionDate":"2028-05"},{"nctId":"NCT05294588","phase":"PHASE2","title":"Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2022-04-18","conditions":["Gonorrhea Male"],"enrollment":65,"completionDate":"2026-02-05"},{"nctId":"NCT05980871","phase":"PHASE4","title":"Treatment Responses of Early Syphilis to Ceftriaxone Plus Doxycycline","status":"TERMINATED","sponsor":"National Taiwan University Hospital","startDate":"2023-03-10","conditions":["Early Syphilis"],"enrollment":109,"completionDate":"2025-07-25"},{"nctId":"NCT06819592","phase":"PHASE3","title":"PRophylaxis Against Early VENTilator-associated Infections in Acute Brain Injury","status":"RECRUITING","sponsor":"The George Institute","startDate":"2025-10-30","conditions":["All-cause Mortality","Quality of Life","Disability, Intellectual","Neurological Disorder","Acute Brain Injury","Ventilation, Mechanical","Intensive Care Medicine"],"enrollment":3300,"completionDate":"2029-12"},{"nctId":"NCT02701595","phase":"PHASE3","title":"Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Streptococcus","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2016-02-29","conditions":["Infective Endocarditis"],"enrollment":324,"completionDate":"2023-06-24"},{"nctId":"NCT05750966","phase":"NA","title":"Short-course Antibiotics vs Standard Course Antibiotics in Patients With Cholangitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2023-07-19","conditions":["Cholangitis"],"enrollment":440,"completionDate":"2026-09-01"},{"nctId":"NCT04986254","phase":"","title":"PNEUmonia DOSing in Critically Ill Patients (PNEUDOS)","status":"COMPLETED","sponsor":"The University of Queensland","startDate":"2019-10-17","conditions":["Pneumonia"],"enrollment":179,"completionDate":"2024-01-31"},{"nctId":"NCT06396078","phase":"PHASE4","title":"Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT)","status":"RECRUITING","sponsor":"Ohio State University","startDate":"2024-07-18","conditions":["Preterm Premature Rupture of Membrane","Pregnancy, High Risk","Preterm Birth"],"enrollment":56,"completionDate":"2026-12"},{"nctId":"NCT04349826","phase":"PHASE4","title":"The Azithromycin and Cefixime Treatment of Typhoid in South Asia Trial (ACT-South Asia Trial)","status":"COMPLETED","sponsor":"Oxford University Clinical Research Unit, Vietnam","startDate":"2021-05-23","conditions":["Typhoid Fever"],"enrollment":2150,"completionDate":"2025-12-31"},{"nctId":"NCT05074147","phase":"PHASE3","title":"Comparison Between Two Durations of Antibiotherapy for Non-surgically-treated Diabetic Foot Osteomyelitis (CHRONOS-2)","status":"WITHDRAWN","sponsor":"Tourcoing Hospital","startDate":"2022-05-01","conditions":["Osteomyelitis - Foot"],"enrollment":0,"completionDate":"2026-11"},{"nctId":"NCT05079620","phase":"PHASE4","title":"Early Antibiotics After Aspiration in ICU Patients","status":"TERMINATED","sponsor":"UConn Health","startDate":"2021-11-30","conditions":["Aspiration","Aspiration Pneumonia"],"enrollment":5,"completionDate":"2024-04-12"},{"nctId":"NCT07308457","phase":"NA","title":"Enhanced Molecular Microbiological Surveillance Versus Ceftriaxone Prophylaxis in Hematopoietic Cell Transplant Patients","status":"RECRUITING","sponsor":"Pomeranian Medical University Szczecin","startDate":"2024-09-01","conditions":["Incidence of Infectious Diseases"],"enrollment":100,"completionDate":"2027-10-31"},{"nctId":"NCT07236944","phase":"PHASE4","title":"Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care","status":"RECRUITING","sponsor":"Uppsala University","startDate":"2025-12","conditions":["Febrile Urinary Tract Infection"],"enrollment":560,"completionDate":"2029-03"},{"nctId":"NCT06294600","phase":"PHASE3","title":"Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)","status":"RECRUITING","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2024-02-12","conditions":["Community-acquired Pneumonia"],"enrollment":330,"completionDate":"2026-07-30"},{"nctId":"NCT03012360","phase":"PHASE4","title":"Antimicrobial Treatment in Patients With Ventilator-associated Tracheobronchitis","status":"TERMINATED","sponsor":"University Hospital, Lille","startDate":"2018-02-08","conditions":["Mechanical Ventilation Complication","Critical Illness"],"enrollment":103,"completionDate":"2024-07-07"},{"nctId":"NCT02473263","phase":"PHASE3","title":"Samu Save Sepsis: Early Goal Directed Therapy in Pre Hospital Care of Patients With Severe Sepsis and/or Septic Shock","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-05-09","conditions":["Severe Septic Syndrome (Severe Sepsis and Septic Shock) Diagnosed and Treated by Mobile Intensive Care Unit"],"enrollment":398,"completionDate":"2019-02-09"},{"nctId":"NCT07229755","phase":"PHASE2,PHASE3","title":"Comparison Between Effect of Empirical Antibiotic Prophylaxis Versus Enhanced Prophylactic Measures on Rate of Urinary Tract Infection After Flexible Ureteroscopy in Children With Pyuria","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2024-07-01","conditions":["Urinary Tract Infection (Diagnosis)"],"enrollment":140,"completionDate":"2025-02-05"},{"nctId":"NCT03269994","phase":"PHASE3","title":"Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-11-21","conditions":["Pancreatic Cancer","Pancreas Cancer","Pancreatic Diseases"],"enrollment":967,"completionDate":"2025-01-28"},{"nctId":"NCT03959527","phase":"PHASE3","title":"Zoliflodacin in Uncomplicated Gonorrhoea","status":"COMPLETED","sponsor":"Global Antibiotics Research and Development Partnership","startDate":"2019-11-06","conditions":["Gonorrhea"],"enrollment":1011,"completionDate":"2023-09-18"},{"nctId":"NCT05253339","phase":"NA","title":"The Expected Advantage of Administering Prophylactic Antibiotics Using Target- Concentration Controlled Infusion","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2022-04-04","conditions":["Anti-bacterial Agents","Pharmacokinetics","General Surgery"],"enrollment":2494,"completionDate":"2025-08-28"},{"nctId":"NCT03413384","phase":"PHASE2","title":"To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia","status":"ACTIVE_NOT_RECRUITING","sponsor":"BrainX Corporation","startDate":"2019-02-15","conditions":["Parkinson's Disease Dementia"],"enrollment":100,"completionDate":"2025-12-31"},{"nctId":"NCT03068741","phase":"PHASE4","title":"Paramedic Initiated Treatment of Sepsis Targeting Out-of-hospital Patients (PITSTOP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dr. Damon Scales","startDate":"2020-03-23","conditions":["Severe Sepsis or Septic Shock"],"enrollment":2040,"completionDate":"2025-12"},{"nctId":"NCT05121974","phase":"PHASE2","title":"Tebipenem Trial in Children With Shigellosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2022-08-18","conditions":["Shigellosis"],"enrollment":132,"completionDate":"2026-08-17"},{"nctId":"NCT04310930","phase":"PHASE2,PHASE3","title":"Finding the Optimal Regimen for Mycobacterium Abscessus Treatment","status":"RECRUITING","sponsor":"The University of Queensland","startDate":"2020-03-02","conditions":["Pulmonary Disease Due to Mycobacteria (Diagnosis)"],"enrollment":300,"completionDate":"2030-06-30"},{"nctId":"NCT02996656","phase":"NA","title":"Antimicrobial Prophylaxis for Skin Colonization With Propionibacterium Acnes in Primary Open Shoulder Surgery","status":"RECRUITING","sponsor":"Université de Montréal","startDate":"2016-12","conditions":["Propionibacterium Infection"],"enrollment":88,"completionDate":"2026-12"},{"nctId":"NCT06423898","phase":"PHASE4","title":"Ampicillin and Ceftriaxone for the Treatment of Enterococcus Faecalis Infective Endocarditis.","status":"RECRUITING","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2024-10-09","conditions":["Endocarditis, Infective"],"enrollment":284,"completionDate":"2028-12-31"},{"nctId":"NCT05821478","phase":"PHASE3","title":"Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients","status":"RECRUITING","sponsor":"Institut Pasteur","startDate":"2025-05-22","conditions":["Hidradenitis Suppurativa"],"enrollment":92,"completionDate":"2028-02-27"},{"nctId":"NCT07043855","phase":"NA","title":"Duration of Perioperative Antibiotics in Pancreatoduodenectomy","status":"NOT_YET_RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-08","conditions":["Pancreatoduodenectomy","PPPD","Infectious Complications"],"enrollment":558,"completionDate":"2027-10"},{"nctId":"NCT04282785","phase":"","title":"Point-of-care Monitoring of Antibiotic Concentration in Blood With UV-VIS Absorption Spectroscopy","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2022-08-01","conditions":["Sepsis","Infection, Bacterial"],"enrollment":36,"completionDate":"2023-08-10"},{"nctId":"NCT05426499","phase":"","title":"Translational PKPD Modeling of Anti-infective Drugs Used in Pediatric Units.","status":"RECRUITING","sponsor":"Poznan University of Medical Sciences","startDate":"2021-10-01","conditions":["Population Modeling of Anti-infective Drugs"],"enrollment":150,"completionDate":"2025-09-30"},{"nctId":"NCT04999592","phase":"PHASE2","title":"Ceftriaxone to PRevent pneumOnia and inflammatTion aftEr Cardiac arresT (PROTECT)","status":"TERMINATED","sponsor":"David J. Gagnon","startDate":"2021-08-20","conditions":["Out-Of-Hospital Cardiac Arrest","Pneumonia"],"enrollment":53,"completionDate":"2024-11-01"},{"nctId":"NCT06907316","phase":"PHASE4","title":"Cefixime Versus Benzathine Penicillin G in Treatment of Early Syphilis","status":"TERMINATED","sponsor":"Bulovka Hospital","startDate":"2021-07-13","conditions":["Syphilis"],"enrollment":61,"completionDate":"2024-08-01"},{"nctId":"NCT04975945","phase":"PHASE4","title":"Assessing Parenteral Antibiotics Versus Single-time Intra-operative Intra-dermal Antibiotic Administration for Prevention of SSI","status":"WITHDRAWN","sponsor":"The Grant Medical College & Sir J.J. Group of Hospitals","startDate":"2021-08","conditions":["Surgical Wound Infection","Surgical Site Infection"],"enrollment":0,"completionDate":"2022-01"},{"nctId":"NCT05470517","phase":"PHASE2","title":"Antibiotic Instillation in Appendicitis","status":"COMPLETED","sponsor":"Johns Hopkins All Children's Hospital","startDate":"2023-01-05","conditions":["Complicated Appendicitis","Acute Appendicitis"],"enrollment":190,"completionDate":"2024-03-20"},{"nctId":"NCT04958122","phase":"PHASE3","title":"Cefixime Clinical Trial","status":"RECRUITING","sponsor":"University of Southern California","startDate":"2021-06-20","conditions":["Syphilis","Human Immunodeficiency Virus"],"enrollment":400,"completionDate":"2027-06-30"},{"nctId":"NCT06828952","phase":"","title":"Risk Factors of Failure of Conservative Treatment in Acute Non Complicated Appendicitis","status":"NOT_YET_RECRUITING","sponsor":"Ahmed Mohammed Hussein Sayed","startDate":"2025-06-22","conditions":["Conservative Management"],"enrollment":100,"completionDate":"2025-12-02"},{"nctId":"NCT05929599","phase":"NA","title":"Efficacy of LiveSpo Navax in Supportive Treatment of Pneumonia in Children With RSV and Bacterial Co-infections","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Children's Hospital, Vietnam","startDate":"2023-07-05","conditions":["Acute Respiratory Tract Infections","Pneumonia","Respiratory Syncytial Virus (RSV)"],"enrollment":120,"completionDate":"2025-03"},{"nctId":"NCT06166381","phase":"NA","title":"Parenteral Versus Combined Parenteral With Vancomycin-soaked Graft in ACL Reconstruction","status":"RECRUITING","sponsor":"University of Duhok","startDate":"2024-01-25","conditions":["Infection, Bacterial"],"enrollment":288,"completionDate":"2025-02"},{"nctId":"NCT05849090","phase":"EARLY_PHASE1","title":"Vancomycin and Tobramycin Powder Use in Acute Open Fractures","status":"COMPLETED","sponsor":"University of Utah","startDate":"2023-03-27","conditions":["Infections"],"enrollment":10,"completionDate":"2024-12-12"},{"nctId":"NCT06044272","phase":"","title":"Antimicrobial Resistance in Hospitals From Meta, Colombia","status":"COMPLETED","sponsor":"Hospital Departamental de Villavicencio","startDate":"2023-09-01","conditions":["Increased Drug Resistance"],"enrollment":10000,"completionDate":"2024-06-30"},{"nctId":"NCT06616168","phase":"PHASE1","title":"Urogenital Infections in Women of Reproductive Age and the Activity of 4-Thiazolidinone Derivatives Against Pathogens","status":"ACTIVE_NOT_RECRUITING","sponsor":"Danylo Halytsky Lviv National Medical University","startDate":"2023-09-01","conditions":["Bacterial Vaginosis"],"enrollment":200,"completionDate":"2027-08-31"},{"nctId":"NCT06572761","phase":"PHASE3","title":"A Combination of Antibiotics to Decrease Neonatal Morbidity and Mortality for Previable Threatened Labor","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-09","conditions":["Previable Labour With Intact Membranes"],"enrollment":350,"completionDate":"2028-05"},{"nctId":"NCT05804123","phase":"NA","title":"LiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis Media","status":"COMPLETED","sponsor":"Anabio R&D","startDate":"2021-10-28","conditions":["Upper Respiratory Tract Infections"],"enrollment":175,"completionDate":"2024-08-01"},{"nctId":"NCT05027516","phase":"PHASE4","title":"Trial Comparing Ceftriaxone Plus Azithromycin Versus Ceftriaxone for the Treatment of Gonorrhea","status":"COMPLETED","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2022-01-17","conditions":["Neisseria Gonorrhoeae"],"enrollment":42,"completionDate":"2022-05-09"},{"nctId":"NCT06532409","phase":"NA","title":"Comparison of Efficacy of Oral Amoxicillin Versus Intravenous Ceftriaxone","status":"NOT_YET_RECRUITING","sponsor":"RESnTEC, Institute of Research","startDate":"2024-10-01","conditions":["Community-acquired Pneumonia"],"enrollment":114,"completionDate":"2025-09-30"},{"nctId":"NCT06527989","phase":"PHASE2,PHASE3","title":"Prophylactic Antibiotic in Subtalar Fusion Surgery","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-09-01","conditions":["Surgical Site Infection"],"enrollment":102,"completionDate":"2025-11-01"},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":["Community-acquired Pneumonia, Influenza, COVID-19"],"enrollment":20000,"completionDate":"2028-02"},{"nctId":"NCT04041791","phase":"PHASE3","title":"A Study to Compare Different Antibiotics and Different Modes of Fluid Treatment for Children With Severe Pneumonia","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-08-19","conditions":["Pneumonia"],"enrollment":4392,"completionDate":"2024-04-05"},{"nctId":"NCT06454643","phase":"NA","title":"Gentamicin in Cardiac Surgery","status":"COMPLETED","sponsor":"Al-Rasheed University College","startDate":"2020-01-01","conditions":["Cardiac Infection"],"enrollment":50,"completionDate":"2021-01-01"},{"nctId":"NCT02784821","phase":"PHASE2","title":"Antibiotic \"Dysbiosis\" in Preterm Infants","status":"COMPLETED","sponsor":"University of Florida","startDate":"2017-01-16","conditions":["Enterocolitis, Necrotizing","Bacteremia","Bronchopulmonary Dysplasia","Intraventricular Hemorrhage","Periventricular Leukomalacia","Chronic Lung Disease","Ileal Perforation"],"enrollment":98,"completionDate":"2019-09-11"},{"nctId":"NCT04010539","phase":"PHASE3","title":"A Study Evaluating Efficacy and Safety of Gepotidacin Compared With Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-10-21","conditions":["Gonorrhea"],"enrollment":628,"completionDate":"2023-10-10"},{"nctId":"NCT02424461","phase":"PHASE3","title":"Antibiotic Treatment for 7 Days Versus 14 Days in Patients With Acute Male Urinary Tract Infection","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-01-25","conditions":["Acute Male Urinary Tract Infection"],"enrollment":274,"completionDate":"2019-07-25"},{"nctId":"NCT05755789","phase":"PHASE3","title":"Intermittent Cefoxitin Administration Versus Loading Bolus Followed by Continuous Infusion for the Prevention of Surgical Site Infection in Colorectal Surgery","status":"RECRUITING","sponsor":"Poitiers University Hospital","startDate":"2023-06-22","conditions":["Antibiotic Prophylaxis","Colorectal Surgery"],"enrollment":2000,"completionDate":"2025-06"},{"nctId":"NCT06349122","phase":"PHASE4","title":"Screen-and-treat Strategy for Vaginal Flora Abnormalities in Pregnant Women at High Risk of Preterm Birth","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2024-08","conditions":["Bacterial Vaginosis","Vaginal Dysbiosis","Premature Delivery"],"enrollment":1292,"completionDate":"2028-01"},{"nctId":"NCT03681431","phase":"PHASE2","title":"Evaluation of an Antibiotic Regimen Pharmacokinetic Applicable to Enterococcus Faecalis Infective Endocarditis","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2018-04-23","conditions":["Infectious Endocarditis"],"enrollment":12,"completionDate":"2019-05-23"},{"nctId":"NCT04873778","phase":"NA","title":"Comparing Effects of Kinesio and Dynamic Tapings in Postpartum Women With Pelvic Girdle Pain","status":"COMPLETED","sponsor":"National Cheng Kung University","startDate":"2020-10-05","conditions":["Pelvic Girdle Pain"],"enrollment":57,"completionDate":"2021-05-01"},{"nctId":"NCT06291181","phase":"NA","title":"Studying the Distribution of Accessory Gene Regulator (Agr) Quorum Sensing System and the Prevalence of Linezolid and Mupirocin Resistance in Biofilm Producer/Non Producer Staphylococcus Aureus in Sohag University Hospitals","status":"COMPLETED","sponsor":"Sohag University","startDate":"2023-01-01","conditions":["Staphylococcus Aureus"],"enrollment":265,"completionDate":"2023-06-30"},{"nctId":"NCT05761405","phase":"EARLY_PHASE1","title":"Potentiated Aminoglycosides in Postoperative Urinary Tract Infection Prophylaxis","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2024-01-16","conditions":["Urinary Tract Infections","Urological System Complication of Procedure"],"enrollment":90,"completionDate":"2026-04-15"},{"nctId":"NCT03897582","phase":"","title":"Beta-Lactams Dosing In Pneumonia in ICU in Patients Treated by Continuous Renal Replacement Therapy: the BLIPIC Study","status":"RECRUITING","sponsor":"Centre Hospitalier de Valenciennes","startDate":"2019-02-22","conditions":["Beta-lactam","Continuous Renal Replacement Therapy","Pneumonia","Antibiotic"],"enrollment":65,"completionDate":"2026-05-31"},{"nctId":"NCT06220929","phase":"PHASE4","title":"Mecobalamin Combined With Ceftriaxone Sodium in the Treatment of Sepsis Liver Injury","status":"UNKNOWN","sponsor":"Sichuan Provincial People's Hospital","startDate":"2024-01-15","conditions":["Sepsis","Liver Dysfunction"],"enrollment":40,"completionDate":"2025-01-01"},{"nctId":"NCT05156437","phase":"PHASE4","title":"Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)","status":"ENROLLING_BY_INVITATION","sponsor":"Vinay Badhwar","startDate":"2022-03-16","conditions":["Endocarditis"],"enrollment":20,"completionDate":"2024-10"},{"nctId":"NCT05199324","phase":"PHASE4","title":"Early Oral Step-down Antibiotic Therapy for Uncomplicated Gram-negative Bacteraemia","status":"UNKNOWN","sponsor":"Tan Tock Seng Hospital","startDate":"2022-04-01","conditions":["Gram-negative Bacteraemia"],"enrollment":720,"completionDate":"2025-06-01"},{"nctId":"NCT03179384","phase":"PHASE4","title":"Impact on the Intestinal Microbiota of Treatment With Ceftriaxone in Women's Acute Community Pyelonephritis","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2017-06-26","conditions":["Pyelonephritis Acute"],"enrollment":9,"completionDate":"2019-02-05"},{"nctId":"NCT06090565","phase":"PHASE4","title":"Cefixime Plus Doxycycline Compared to Ceftriaxone Plus Azithromycin for Treatment of Gonorrhoea","status":"COMPLETED","sponsor":"Bulovka Hospital","startDate":"2021-04-01","conditions":["Gonorrhea"],"enrollment":161,"completionDate":"2022-12-22"},{"nctId":"NCT02021006","phase":"PHASE3","title":"Antibiotic Prophylaxis and Renal Damage In Congenital Abnormalities of the Kidney and Urinary Tract","status":"UNKNOWN","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2013-12","conditions":["Vesicoureteral Reflux","Renal Hypodysplasia, Nonsyndromic, 1","Chronic Kidney Disease"],"enrollment":292,"completionDate":"2025-01"},{"nctId":"NCT05149287","phase":"PHASE2","title":"PROPER Trial of Pain and Inflammation After Knee Arthroscopy","status":"TERMINATED","sponsor":"Austin V Stone","startDate":"2021-12-28","conditions":["Meniscus Tear","Meniscus Lesion","Cartilage Injury"],"enrollment":5,"completionDate":"2022-04-29"},{"nctId":"NCT02389036","phase":"PHASE3","title":"Selective Decontamination of the Digestive Tract in Intensive Care Unit Patients","status":"COMPLETED","sponsor":"The George Institute","startDate":"2017-05-01","conditions":["Critical Illness","Sepsis","Septic Shock","Ventilator Associated Pneumonia"],"enrollment":20010,"completionDate":"2023-04-26"},{"nctId":"NCT05971550","phase":"PHASE3","title":"Clearance of Asymptomatic Pharyngeal Carriage of Neisseria Gonorrhoeae With or Without Ceftriaxone Treatment: Randomized Non-inferiority Study","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-09","conditions":["Neisseria Gonorrhoeae Infection","Asymptomatic Pharyngeal Carriage"],"enrollment":254,"completionDate":"2025-12"},{"nctId":"NCT05943223","phase":"PHASE2","title":"Piperacillin/Tazobactam Versus ceftriAxone and Metronidazole for Children With Perforated Appendicitis (ALPACA)","status":"UNKNOWN","sponsor":"McMaster Children's Hospital","startDate":"2024-01","conditions":["Appendicitis Perforated"],"enrollment":16,"completionDate":"2024-12"},{"nctId":"NCT05398081","phase":"PHASE2","title":"Cefuroxime vs Ceftriaxone for SSI Prevention in Neurosurgery","status":"COMPLETED","sponsor":"Dr. Promise Tamunoipiriala Jaja","startDate":"2021-12-01","conditions":["Surgical Site Infection","Antibiotics Prophylaxis"],"enrollment":96,"completionDate":"2022-03-05"},{"nctId":"NCT00138801","phase":"PHASE3","title":"Effect of Intravenous Ceftriaxone and Oral Doxycycline for Lyme Neuroborreliosis","status":"COMPLETED","sponsor":"Sorlandet Hospital HF","startDate":"2004-03","conditions":["Lyme Neuroborreliosis"],"enrollment":120,"completionDate":"2008-12"},{"nctId":"NCT02800785","phase":"NA","title":"The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial","status":"COMPLETED","sponsor":"University of Washington","startDate":"2016-05","conditions":["Appendicitis"],"enrollment":1552,"completionDate":"2021-09-01"},{"nctId":"NCT03087656","phase":"PHASE4","title":"Antibiotics to Decrease Post ERCP Cholangitis","status":"UNKNOWN","sponsor":"University of Southern California","startDate":"2017-03-29","conditions":["Cholangitis"],"enrollment":200,"completionDate":"2024-02-23"},{"nctId":"NCT04218695","phase":"PHASE4","title":"Prophylactic Antibiotics in Admitted Cirrhotics","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2020-08-24","conditions":["Cirrhosis, Liver"],"enrollment":32,"completionDate":"2021-08-28"},{"nctId":"NCT05707533","phase":"","title":"Vaginal Adventitia Reserved and Anatomical Implant Technique of Transvaginal Mesh Procedure for Pelvic Organ Prolapse","status":"COMPLETED","sponsor":"West China Hospital","startDate":"2022-08-01","conditions":["Pelvic Organ Prolapse"],"enrollment":589,"completionDate":"2022-11-30"},{"nctId":"NCT05654896","phase":"PHASE3","title":"Prophylactic Antibiotic Use in Transarterial Chemoembolization for Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Nadeem Iqbal","startDate":"2022-11-26","conditions":["Antibiotic Prophylaxis"],"enrollment":158,"completionDate":"2023-12-26"},{"nctId":"NCT00591318","phase":"PHASE1,PHASE2","title":"A Placebo-controlled Efficacy Study of IV Ceftriaxone for Refractory Psychosis","status":"TERMINATED","sponsor":"Research Foundation for Mental Hygiene, Inc.","startDate":"2007-10-10","conditions":["Psychosis","Schizophrenia","Schizoaffective Disorder"],"enrollment":12,"completionDate":"2011-03-17"},{"nctId":"NCT02334124","phase":"NA","title":"Comparing the Intravenous Treatment of Skin Infections in Children, Home Versus Hospital","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2015-01","conditions":["Cellulitis"],"enrollment":190,"completionDate":"2022-11"},{"nctId":"NCT05606302","phase":"","title":"A Multi-center Clinical Study of Drug Antibody and Precision Transfusion in China","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2021-10-01","conditions":["Drug-specific Antibodies"],"enrollment":14000,"completionDate":"2023-12"},{"nctId":"NCT03660488","phase":"PHASE2","title":"Cefixime for Alternative Syphilis Treatment","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2018-09-03","conditions":["Syphilis","Early Syphilis"],"enrollment":58,"completionDate":"2021-01-30"},{"nctId":"NCT05427747","phase":"PHASE4","title":"Meropenem vs Cefotaxime as Empirical Treatment of SBP","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-01-01","conditions":["Spontaneous Bacterial Peritonitis"],"enrollment":286,"completionDate":"2024-02"},{"nctId":"NCT05027893","phase":"NA","title":"Complications After Lower Third Molar Surgery","status":"UNKNOWN","sponsor":"University of Novi Sad","startDate":"2019-06-07","conditions":["Postoperative Complications","Antibiotic Reaction","Antibiotic Side Effect","Antibiotic Resistant Infection","Antibiotic Resistant Strain","Infection, Bacterial","Infection, Laboratory"],"enrollment":157,"completionDate":"2023-12-31"},{"nctId":"NCT05417997","phase":"PHASE3","title":"Effect of Kunamin in SARS-CoV-2 RT-PCR Positive Covid-19 Patients","status":"COMPLETED","sponsor":"RAAS Nutritionals, LLC","startDate":"2021-05-29","conditions":["COVID-19 Respiratory Infection","FLU","Cold; Influenza","Bacterial Pneumonia","COVID-19 Pneumonia"],"enrollment":71,"completionDate":"2021-12-02"},{"nctId":"NCT03440216","phase":"NA","title":"Population Pharmacokinetics and Pharmacodynamics of Beta-lactams of Interest in Adult Patients From Intensive Care Units","status":"UNKNOWN","sponsor":"Université Catholique de Louvain","startDate":"2018-03-15","conditions":["Pharmacokinetics","Anti-Bacterial Agents","Infection, Bacterial","Infections, Respiratory","Infection","Drug Monitoring"],"enrollment":20,"completionDate":"2022-12-15"},{"nctId":"NCT05378022","phase":"NA","title":"Effects of Nasal-spraying LiveSpo Navax in Treatment of Influenza Virus in Children","status":"COMPLETED","sponsor":"National Children's Hospital, Vietnam","startDate":"2020-12-21","conditions":["Acute Respiratory Tract Infections"],"enrollment":70,"completionDate":"2022-04-22"},{"nctId":"NCT05375240","phase":"PHASE2","title":"Propranolol on Post Stroke Immune Status and Infection","status":"UNKNOWN","sponsor":"Tianjin Medical University General Hospital","startDate":"2022-06","conditions":["Stroke","Cerebrovascular Disorders","Ischemic Stroke","Brain Diseases","Central Nervous System Diseases","Nervous System Diseases","Cardiovascular Diseases","Propranolol","Beta Blocker","Molecular Mechanisms of Pharmacological Action","Immunologic Factors","Physiological Effects of Drugs"],"enrollment":45,"completionDate":"2024-06"},{"nctId":"NCT05308849","phase":"NA","title":"Peritoneal Diffusion and Efficacy of Antibiotic Therapy in Pediatric Peritonitis","status":"UNKNOWN","sponsor":"Central Hospital, Nancy, France","startDate":"2022-03-31","conditions":["Peritonitis","Appendicitis","Children, Only","Antibiotic Toxicity"],"enrollment":41,"completionDate":"2024-06-30"},{"nctId":"NCT05216744","phase":"PHASE2","title":"Comparison of Efficacy of Two Combination Regimens for the Neisseria Gonorrhoeae and Chlamydia Coinfection","status":"COMPLETED","sponsor":"Haiphong University of Medicine and Pharmacy","startDate":"2021-07-15","conditions":["Neisseria Gonorrhoeae Infection","Chlamydia Trachomatis Infection"],"enrollment":125,"completionDate":"2022-02-20"},{"nctId":"NCT02596503","phase":"PHASE1","title":"A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2015-10-21","conditions":["Relapsed Solid Tumors","Refractory Solid Tumors"],"enrollment":2,"completionDate":"2020-01-24"},{"nctId":"NCT05164692","phase":"NA","title":"Effects of Nasal-spraying LiveSpo Navax in Treatment of Acute Respiratory Infections in Children","status":"COMPLETED","sponsor":"National Children's Hospital, Vietnam","startDate":"2020-08-29","conditions":["Acute Respiratory Tract Infections"],"enrollment":100,"completionDate":"2021-08-29"},{"nctId":"NCT04870138","phase":"PHASE1","title":"Experimental Human Infection With Neisseria Gonorrhoeae (LptA Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-03-10","conditions":["Gonococcal Infection"],"enrollment":16,"completionDate":"2015-04-28"},{"nctId":"NCT00000648","phase":"NA","title":"A Pilot Study Evaluating Penicillin G and Ceftriaxone as Therapies for Presumed Neurosyphilis in HIV Seropositive Individuals","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections","Neurosyphilis"],"enrollment":100,"completionDate":"1996-02"},{"nctId":"NCT05051163","phase":"PHASE2,PHASE3","title":"Strategies to Reduce Mortality Among HIV-infected and HIV-exposed Children Admitted With Severe Acute Malnutrition","status":"UNKNOWN","sponsor":"Makerere University","startDate":"2021-06-14","conditions":["HIV-1-infection","Malnutrition, Child"],"enrollment":300,"completionDate":"2024-06-14"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intramuscular","formulation":"Injection, Powder","formulations":[{"form":"INJECTION","route":"INTRAVENOUS","productName":"Cefotaxime"},{"form":"INJECTION, POWDER, FOR SOLUTION","route":"INTRAMUSCULAR","productName":"CEFOTAXIME"},{"form":"INJECTION, POWDER, FOR SOLUTION","route":"INTRAMUSCULAR","productName":"Cefotaxime"},{"form":"POWDER, FOR SOLUTION","route":"INTRAMUSCULAR","productName":"Cefotaxime"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000147755","MMSL":"42787","NDDF":"002727","UNII":"N2GI8B1GK7","VUID":"4019663","CHEBI":"CHEBI:3498","VANDF":"4018466","INN_ID":"4504","RXNORM":"203117","UMLSCUI":"C0007554","chemblId":"CHEMBL1010","ChEMBL_ID":"CHEMBL1010","KEGG_DRUG":"D00919","DRUGBANK_ID":"DB00493","PDB_CHEM_ID":" CE3","PUBCHEM_CID":"10695961","SNOMEDCT_US":"3334000","IUPHAR_LIGAND_ID":"10893","SECONDARY_CAS_RN":"64485-93-4","MESH_DESCRIPTOR_UI":"D002439"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1981-","companyName":"Sanofi","relationship":"Original Developer"},{"period":"present","companyName":"Sterimax","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"1.2 hours","clearance":"2.7 mL/min/kg","fractionUnbound":"0.6%","volumeOfDistribution":"0.19 L/kg"},"publicationCount":10685,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"J01DD01","allCodes":["J01DD01","J01DD51"]},"biosimilarFilings":[],"originalDeveloper":"Sanofi Aventis Us","recentPublications":[{"date":"2026 Feb 27","pmid":"41901706","title":"Fluoroquinolone-Resistant Avian Pathogenic Escherichia coli Isolated from Asymptomatic Broiler Chickens in a Slaughterhouse in Northern Thailand.","journal":"Pathogens (Basel, Switzerland)"},{"date":"2026 Mar 27","pmid":"41893986","title":"Evaluation of the B-lactam antibiotic concentration in the early phase of treatment of patients with suspected sepsis at the emergency department.","journal":"Infection"},{"date":"2026 Mar 23","pmid":"41892484","title":"Antimicrobial Resistance and ESBL-Associated Predictors Among Uropathogens: A 2019-2024 Isolate-Level Study.","journal":"Antibiotics (Basel, Switzerland)"},{"date":"2026 Jun","pmid":"41890979","title":"Phenotypic and genotypic characterization of Acinetobacter junii and Acinetobacter nosocomialis isolated from humans, animals, and the environment in Lagos, Nigeria.","journal":"One health (Amsterdam, Netherlands)"},{"date":"2026 Jan-Mar","pmid":"41890384","title":"Analysis of Antimicrobial Utilization Pattern in Neonatal Intensive Care Unit: A Prospective Observational Study.","journal":"Journal of pharmacy & bioallied sciences"}],"companionDiagnostics":[],"genericManufacturers":10,"_genericFilersChecked":true,"genericManufacturerList":["Aurobindo Pharma","Aurobindo Pharma Ltd","Cephazone Pharma","Fresenius Kabi Usa","Hikma","Hospira","Hospira Inc","Lupin","Sanofi Aventis Us","Wockhardt"],"status":"approved","companyName":"Sterimax","companyId":"sterimax","modality":"Small molecule","firstApprovalDate":"1981","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2002-11-20T00:00:00.000Z","mah":"HIKMA","brand_name_local":null,"application_number":"ANDA065071"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2020-06-04T00:00:00.000Z","mah":"HIKMA","brand_name_local":null,"application_number":"ANDA065072"},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:35:47.901823+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}